glp-1 medication competitors pharmaceutical companies Harvard Business Review | A PwC analysis shows that medications like Ozempic and Zepbound may be catalyzing a behavioral and economic shift on par with major GLP-1 Receptor Agonist Market Size

This is a reason why GLP-1 medications work best within a broader health program that includes nutrition guidance and physical activity rather than as a standalone intervention

GLP-1 Market: Key Segments Currently, Small Molecule Segment Occupies the Largest Share of the GLP-1 Market In terms of type of molecule, the market is segmented into biologics and small molecules

Diabetes Care 38(5):752759

Doering, C

doi: 10.1016/j.arr.2023.101979 70

However, the absence of statistically significant effects of GLP-1R agonists, with respect to at least one fibrosis stage histological improvement without worsening of NASH, could be the result of: (i) the insufficient duration of the current studies